ANXA1 and neoplasm: Although we did not observe a significant difference in the number of CD31-positive blood vessels per tumor area between groups, IF7-10B drug-mediated BNCT may destroy Anxa1-positive tumor vasculature as a way of boosting BNCT therapeutic potential (Fig. 6).